Singapore markets closed

Twist Bioscience Corporation (TWST)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
27.95-0.41 (-1.45%)
At close: 04:00PM EDT
27.95 0.00 (0.00%)
After hours: 04:20PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close28.36
Open28.39
Bid27.89 x 100
Ask27.97 x 100
Day's range27.41 - 29.20
52-week range11.46 - 43.21
Volume1,089,834
Avg. volume876,956
Market cap1.616B
Beta (5Y monthly)1.62
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Business Wire

    Twist Bioscience to Report Fiscal 2024 Second Quarter Financial Results on Thursday, May 2, 2024

    SOUTH SAN FRANCISCO, Calif., April 18, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 second quarter ended March 31, 2024, after market close on Thursday, May 2, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. Eastern Time to discuss i

  • Business Wire

    Twist Bioscience Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations

    SOUTH SAN FRANCISCO, Calif., March 28, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of a new Human Pangenome Spike-in for the Twist Exome 2.0 panel developed to enable researchers to detect a more complete view of genetic variation during whole exome sequencing (WES).

  • Business Wire

    Twist Bioscience Launches IVDR-compliant Precision Dx Products for Whole Exome Sequencing

    SOUTH SAN FRANCISCO, Calif., March 05, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced European Union (EU) in vitro diagnostic regulations (IVDR) compliant Twist Precision Dx next-generation sequencing (NGS) Products.